New hope for kids with rare blood and vessel diseases
NCT ID NCT06512883
Summary
This study is testing a drug called benralizumab in children aged 6 to 18 with rare diseases where high levels of a specific white blood cell (eosinophil) cause inflammation and damage. The main goals are to see if the drug is safe, how it behaves in the body, and if it can help control the diseases. Children will receive injections every 4 weeks for at least one year, with an option to continue for another year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGAurora, Colorado, 80045, United States
-
Research Site
RECRUITINGSão Paulo, 01232-010, Brazil
-
Research Site
RECRUITINGToronto, Ontario, M5G1X8, Canada
-
Research Site
RECRUITINGGuadalajara, 44620, Mexico
-
Research Site
RECRUITINGAltındağ, 06230, Turkey (Türkiye)
-
Research Site
RECRUITINGIstanbul, 34093, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.